Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

Stock Information for Quantum Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quantum Biopharma Ltd.

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.